Powderject 大打撃を与えるd

By This Is Money
Updated: 00:00 BST, 7 December 1999

?

Anglo-U.S. 麻薬 配達／演説／出産 company Powderject 製薬のs saw its 株 大打撃を与えるd on Tuesday after it said it would 延期する the 開始する，打ち上げる of one of its main 製品s. Powderject 株 lost 18.3% by 0945 after it said it was 延期するing the 開始する，打ち上げる of anaesthetic Lidocaine which was earlier 推定する／予想するd to be on the European market in 2000.

Powderject 株 h 広告 lost 180 pence to 802p, 反映するing a 削減 of around £133 million) from its 夜通し capitalisation of around £728 million. The company, which was spun off an Oxford University 研究 team in 1993, said it had now decided to market Lidocaine 共同で as a children's and adult 製品 rather than as adult 構内／化合物 alone.

Powderject's 長，指導者 (n)役員／(a)執行力のある Paul Drayson said the company had taken a 決定／判定勝ち（する） along with partner Celltech Chirsoscience after the 地元の anaesthetic was 設立する to be 井戸／弁護士席-許容するd in children.

Drayson said the company's 決定／判定勝ち（する） was also partly infuenced by the regulators who said that since it was 井戸／弁護士席-許容するd with children there was a 可能性 it would be marketed 非公式に to children even if it was meant for adults.

Powderject will now have その上の 会談 with regulatory 当局 and then decide on a 可能性のある タイミング for regulatory submissions.

The 現在の 可能性のある of 地元の anaesthetics is around $400 million with Xylocaine of AstraZeneca the main player with $240 million in sales.

The company, which 明かすd its half-year results on Tuesday, also said that Roche was dropping its 計画（する）s on その上の work on a 治療力のある protein. Powderject had a を取り引きする Boehinger Mannheim which was recently take over by Roche. Powderject and Roche would now work together to see if any of the スイスの company's 製品s could be used on Powderject's 配達／演説／出産 systems.

The company said its operating cash flow rose to £9.2 million from £4.3 million while it had £73.2 million in cash.

?Reuter